NYSE
TMO
Last Price
US $588.29
KEY FIGURES
MKT CAP
$218.6B
EPS
TTM
$18.81
PEG
TTM
4.29x
P/E
TTM
31.28x
P/S
TTM
4.71x
YIELD
0.31%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
13.35%
Return on equity
ROIC: 7.44%
Valuation History
31.9X
Price to Earnings
EV/EBITDA: 23.7X
Cash flow
Profit margin
6.70%
(FY vs FY)
EBITDA Y/Y
2.55%
(FY vs FY)
Cash flow Y/Y
-1.58%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $588.29
-82.69%
Default assumptions
EBITDA Multiple
Fair Value
Market $588.29
-77.46%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Thermo Fisher Scientific Inc. cash flow to debt ratio of 19.85% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Thermo Fisher Scientific Inc.'s free cash flow has decreased -13.40% from $7.27G last year to $6.29G, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Thermo Fisher Scientific Inc.'s debt to equity ratio is 0.81, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
Thermo Fisher Scientific Inc.'s debt has increased relative to shareholder equity from 0.66 last year to 0.81 today, signaling weakened financials
Financial stability - Net debt/EBITDA.
Thermo Fisher Scientific Inc. has a net debt to EBITDA ratio of 2.58x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Thermo Fisher Scientific Inc.'s interest coverage ratio of 5.59 indicates that earnings with good margin can cover interest payments on company debt
Financial stability - Profit margin growth.
Thermo Fisher Scientific Inc.'s profit margin has increased (1.93%) in the last year from 14.77% to 15.06%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Thermo Fisher Scientific Inc.'s short-term assets of $28.71G exceed its short-term liabilities of $15.19G
Increasing performance - ROA.
Thermo Fisher Scientific Inc.'s return on assets of 6.17% is higher than the 5.00% threshold, indicating efficient asset utilization
Decreasing performance - Absolute return on equity.
Thermo Fisher Scientific Inc.'s return on equity of 13.35%, is lower than 15.00%, indicating bad performance
Increasing performance - Earnings quality.
Thermo Fisher Scientific Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Thermo Fisher Scientific Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Thermo Fisher Scientific Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Thermo Fisher Scientific Inc. has a free cash flow yield of 2.88%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Thermo Fisher Scientific Inc.'s yearly earnings has increased 6.35% since last year from $6.33G to $6.74G, signaling increasing performance
Increasing performance - Healthy revenue growth.
Thermo Fisher Scientific Inc.'s yearly revenue has increased 3.91% since last year from $42.88G to $44.56G, signaling increasing performance
Increasing performance - ROIC.
ROIC 7.44% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Decreasing performance - 3-year revenue CAGR.
Thermo Fisher Scientific Inc.'s 3-year revenue CAGR of -0.27% is negative, indicating declining revenue over the past 3 years
Increasing performance - Revenue consistency.
Thermo Fisher Scientific Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Thermo Fisher Scientific Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Thermo Fisher Scientific Inc. is overvalued relative to its fair value price of 101.82 based on Discounted Cash Flow model
Overvalued - Earnings yield.
Thermo Fisher Scientific Inc. has an earnings yield of 3.20%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
Overvalued - EBITDA valuation.
Thermo Fisher Scientific Inc. is overvalued relative to its fair value price of 132.62 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Thermo Fisher Scientific Inc. has an EV/EBITDA ratio of 21.64x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Overvalued - PEG ratio value.
Thermo Fisher Scientific Inc. has a PEG-ratio over 1 which is considered overvalued
Undervalued - P/B ratio.
Thermo Fisher Scientific Inc. has a price-to-book ratio of 4.14x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Thermo Fisher Scientific Inc. has a price-to-sales ratio of 4.71x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue